For many Duchenne families, halt to gene therapy treatments is heartbreak upon heartbreak
As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are caught in the middle.
Related Articles
6 burning questions about the White House health tech pledge
In this edition of STAT’s Health Tech newsletter: Some questions about the new health tech pledge orchestrated by CMS, and an update on breakthrough devices.
What Vinay Prasad’s ouster means for biotech and the FDA
This week on “The Readout LOUD,” STAT’s biotech reporters parse what Vinay Prasad’s ouster means for biotech and the FDA.
Moderna announces layoffs, and Alnylam’s heart drug sees quick uptake
And other biotech news stories, brought to you by The Readout.
U.S. childhood vaccination rates fall again as exemptions set another record
NEW YORK — U.S. kindergarten vaccination rates inched down again last year and the share of children with exemptions rose to an all-time high, according
U.S. childhood vaccination rates fall again as exemptions set another record
NEW YORK — U.S. kindergarten vaccination rates inched down again last year and the share of children with exemptions rose to an all-time high, according
Senate committee endorses NIH budget increase, rebuking Trump administration’s proposed 40% cut
Senators from both parties endorsed a $400 million increase to the budget of the National Institutes of Health on Thursday
Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine
“It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former professor and friend Adam Cifu.
Senators leave RFK Jr.’s MAHA agency out of 2026 budget in apparent snub
Senators ignored RFK Jr.’s proposal to create a chronic disease agency called the Administration for a Healthy America.
Senators leave RFK Jr.’s MAHA agency out of 2026 budget in apparent snub
Senators ignored RFK Jr.’s proposal to create a chronic disease agency called the Administration for a Healthy America.
Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine
“It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former professor and friend Adam Cifu.